Genomcore Company Profile

Background

Overview

Genomcore is an innovative biotechnology company founded in 2015 and headquartered in Barcelona, Spain. The company specializes in implementing precision medicine through data-driven solutions, aiming to revolutionize healthcare by enhancing patient care and outcomes.

Mission and Vision

Genomcore's mission is to provide advanced personalized health services and bio-health data management, ensuring the protection and confidentiality of clients' personal and genetic data. The company is committed to continuous innovation and the implementation of cutting-edge technologies to ensure the quality and safety of its services.

Primary Area of Focus

The company's primary focus is on the management, interpretation, and storage of complex biomedical data, including genomics, wearables, and medical imaging. Genomcore offers a low-code platform and multimodal data store for precision health, addressing challenges in interoperability, observability, and actionability within the biohealth industry.

Industry Significance

Genomcore holds a unique position as a pioneer in the global market for precision health data management. Its platform is trusted by numerous flagship projects, serving clinical laboratories, pharmaceutical companies, contract research organizations (CROs), diagnostic providers, healthcare professionals, and governments. The company's expertise in managing sensitive personal identifiable information at scale has solidified its reputation as a reliable partner in real-world genomics and biomedical data management projects.

Key Strategic Focus

Core Objectives

• Data Integration and Management: Develop and maintain a platform capable of integrating diverse health data modalities, including genomic, clinical, imaging, and sensor data, into a unified, structured, and scalable environment.

• Compliance and Security: Ensure that all data management processes adhere to stringent regulatory standards, including GDPR, HIPAA, and other relevant regulations, to maintain the confidentiality, integrity, and availability of sensitive health information.

• Innovation in Precision Medicine: Advance the field of precision medicine by providing tools that enable healthcare providers to deliver personalized treatments and real-time insights, thereby improving patient outcomes.

Specific Areas of Specialization

• Biomedical Data Management: Specialize in the secure and scalable management of complex biomedical datasets, facilitating efficient data acquisition, structuring, visualization, analysis, and processing.

• Platform Development: Offer a low-code platform and multimodal data store tailored for precision health, addressing key challenges in data-driven healthcare.

Key Technologies Utilized

• Biomedical Information Management System (BIMS): A proprietary platform designed to integrate and manage diverse health data modalities, supporting the entire biomedical data lifecycle.

• Compliance Frameworks: Implementation of international standards such as ISO/IEC 27001:2022, ISO/IEC 27017:2015, and ISO/IEC 27018:2019 to ensure data security and regulatory compliance.

Primary Markets or Conditions Targeted

• Healthcare Providers: Assist hospitals, clinics, and other healthcare institutions in managing and interpreting complex health data to enhance patient care.

• Pharmaceutical Companies and CROs: Support drug development processes by providing tools for managing clinical trial data and facilitating regulatory compliance.

• Diagnostic Providers: Enable laboratories and diagnostic centers to efficiently handle and analyze biomedical data, improving diagnostic accuracy and speed.

• Governments and Public Health Organizations: Collaborate on national and regional health initiatives, including genome projects and public health studies, to improve population health outcomes.

Financials and Funding

Funding History

• Initial Funding: Genomcore has secured multiple funding rounds to support its growth and technological development.

• Recent Funding Round: In December 2024, the company raised €5 million in a funding round led by QVIDTVM, with the Barça Innovation Hub (BIHUB) also becoming a shareholder.

Notable Investors

• QVIDTVM: A firm focused on long-term investments in mission-driven innovative organizations across the United States and Europe.

• Barça Innovation Hub (BIHUB): The innovation arm of FC Barcelona, which has invested in Genomcore to support advancements in biomedical data management and sports innovation.

Intended Utilization of Capital

The funds from the recent investment are intended to accelerate the development of Genomcore's Biomedical Information Management System (BIMS), enabling the company to enhance its platform's capabilities in integrating and managing diverse health data modalities. This advancement aims to address challenges in data-driven healthcare and support the delivery of personalized treatments and real-time insights.

Pipeline Development

Key Pipeline Candidates

Genomcore's primary focus is on the continuous development and enhancement of its Biomedical Information Management System (BIMS), which serves as the cornerstone of its product offerings. The company does not publicly disclose specific pipeline candidates or products beyond BIMS.

Stages of Clinical Trials or Product Development

• Platform Development: Ongoing development of BIMS to integrate various health data modalities and improve data management capabilities.

• Regulatory Compliance: Ensuring that the platform meets international standards and regulatory requirements for data security and privacy.

Target Conditions

The platform is designed to support a wide range of applications in precision medicine, including but not limited to:

• Genomic Data Analysis: Facilitating the interpretation of genetic information for personalized treatment plans.

• Medical Imaging: Integrating imaging data to enhance diagnostic accuracy and treatment planning.

• Wearable Data Integration: Incorporating data from wearable devices to monitor patient health in real-time.

Relevant Timelines for Anticipated Milestones

Specific timelines for product development milestones are not publicly disclosed. However, the recent investment indicates a strategic focus on accelerating platform development and expanding market reach.

Technological Platform and Innovation

Proprietary Technologies

• Biomedical Information Management System (BIMS): A unique platform that enables the acquisition, structuring, visualization, analysis, and processing of complex health data for precision medicine.

Significant Scientific Methods

• Data Integration Techniques: Utilizing advanced algorithms and data processing methods to integrate diverse health data modalities into a unified system.

• Compliance Frameworks: Implementing international standards such as ISO/IEC 27001:2022, ISO/IEC 27017:2015, and ISO/IEC 27018:2019 to ensure data security and regulatory compliance.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the platform's design suggests potential integration with artificial intelligence and machine learning models to enhance data analysis and interpretation.

Leadership Team

Key Executive Profiles

• Óscar Flores Guri – CEO

Co-founder and CEO of Genomcore, Óscar has been instrumental in driving the company's vision to implement precision medicine in the real world.

• Miquel Àngel Bru – CBDO

Co-founder and Chief Business Development Officer, Miquel brings expertise in business strategy and development, contributing to the company's growth and market expansion.

Key Contributions or Roles Within the Company

• Óscar Flores Guri: Leads the company's strategic direction and oversees the development and implementation of Genomcore's platform and services.

• Miquel Àngel Bru: Focuses on business development, partnerships, and expanding the company's presence in the healthcare and biotechnology sectors.

Competitor Profile

Market Insights and Dynamics

The precision medicine and biomedical data management market is experiencing significant growth, driven by advancements in genomics, personalized healthcare, and data analytics. Companies are increasingly investing in technologies that enable the integration and analysis of complex health data to improve patient outcomes.

Competitor Analysis

Genomcore operates in a competitive landscape with several key players:

• Illumina: A leading provider of sequencing services and products, holding over 80% of the sequencing market.

• Thermo Fisher Scientific: Offers a wide range of products for genomic sequencing, including instruments, reagents, and software.

• Agilent Technologies: Provides lab equipment and consumables necessary for genomic sequencing, serving various applications in research and biotechnology.

• QIAGEN: Offers solutions for genomic sequencing, including instruments, reagents, and software, with a focus on diagnostics and research.